Department of Pharmacy, Kyoto-Katsura Hospital, Kyoto, Japan.
Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan.
Leuk Lymphoma. 2019 Dec;60(12):2975-2981. doi: 10.1080/10428194.2019.1608531. Epub 2019 May 3.
This retrospective cohort study was conducted to investigate the association between prior bortezomib (BOR) therapy and lenalidomide (LEN)-induced rash in multiple myeloma (MM) patients. Eligible MM patients initially treated with LEN were divided into two propensity score-matched cohorts according to the presence or absence of prior BOR therapy. The primary endpoint of the study was rash incidence. We evaluated 144 patients and each cohort contained 43 patients after matching propensity-score. Rash incidence significantly decreased in patients with prior BOR therapy than in those without (30% vs. 53%, < .05). Moreover, patients with rash showed a significantly higher incidence of eosinophilia within 1 month after LEN initiation than those without rash. Our findings indicate that prior BOR therapy may reduce the incidence of LEN-induced rash, which may be characterized by eosinophilia. Accordingly, in patients who discontinued LEN therapy due to rash, LEN re-treatment may be successful after BOR therapy.
这项回顾性队列研究旨在探讨硼替佐米（BOR）治疗史与多发性骨髓瘤（MM）患者来那度胺（LEN）诱导皮疹之间的关联。符合条件的 MM 患者最初接受 LEN 治疗，根据是否存在先前的 BOR 治疗分为两个倾向评分匹配队列。研究的主要终点是皮疹发生率。我们评估了 144 名患者，匹配倾向评分后每个队列包含 43 名患者。先前有 BOR 治疗史的患者皮疹发生率明显低于无 BOR 治疗史的患者（30% vs. 53%，<0.05）。此外，在 LEN 开始后 1 个月内出现皮疹的患者中，嗜酸性粒细胞增多的发生率明显高于无皮疹的患者。我们的研究结果表明，先前的 BOR 治疗可能会降低 LEN 诱导的皮疹发生率，这种皮疹可能伴有嗜酸性粒细胞增多。因此，对于因皮疹而停止 LEN 治疗的患者，在 BOR 治疗后 LEN 再治疗可能会成功。
